Company intelligence / Profile preview

Spexis AG

Ownership: Private
Development stage: Phase 2

Overview

Spexis has multiple clinical candidates in development. ColiFin is approved in Europe for cystic fibrosis and entering global Phase 3 studies. Balixafortide had a negative Phase 3 readout in metastatic breast cancer but is being evaluated for other indications. Lonodelestat and Murepavadin are in earlier clinical development.

Therapeutic areas: OncologyPulmonologyRare Diseases
Modalities: Macrocyclic moleculesInhaled therapeutics
Industry: Biotech

Drug pipeline

5 assets

balixafortide

4 more assets in the full pipeline.

Request access →

Partnerships

Fosun Pharma (China rights to Balixafortide)Santhera (Lonodelestat out-licensed)CF FoundationCARBXIMI

Beyond the preview

Go deeper on Spexis AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spexis AG.

Explore the full profile